Transasia Bio-Medicals reports a significant recovery in revenues and margins amid expanding public-sector projects and regional growth, as it aims to solidify its position among the world’s top in vitro diagnostics firms.
Transasia Bio-Medicals is pressing its case for global relevance after reporting a 13% rise in first-half revenue for fiscal 2027, a pace that the company says is being matched by a modest improvement in margins. The Erba Mannheim group expects EBITDA margin to widen by about 50 basis points to roughly 23%, extending a recovery that has now run for several reporting periods after three years of largely flat trading, according to the company’s own update.
The latest gains matter because they build on a weaker base. Data from The Company Check show Transasia reported revenue of ₹1,450.31 crore in FY 2025, down 9% from the previous year, even though EBITDA reached ₹290.8 crore and the margin held at 20.1%. Against that backdrop, the company’s recent rebound suggests it has been able to stabilise execution and convert a broader portfolio into faster growth.
Management has pointed to operational discipline rather than any single product launch as the main driver. The company says tighter internal reviews, fewer stock shortages, better product quality, closer work with distribution partners, stronger sales incentives and a series of large public-sector wins have all helped. That mix points to a business that is improving day-to-day performance in its core markets while also leaning on government-led healthcare programmes to deepen its reach.
The most visible example is Andhra Pradesh. According to reporting by Medical Buyer and other local accounts, Chief Minister N. Chandrababu Naidu recently flagged off 904 mobile medical units equipped with Transasia instruments as part of the state’s Sanjeevani digital health programme. The state has earmarked about ₹162 crore for the rollout, which is intended to widen preventive screening and build longitudinal health records. An earlier phase in Chittoor district had already enrolled more than 300,000 people, and the programme is targeting screenings for more than 5.6 million people in its first year of full deployment. Transasia believes the units could eventually serve almost 50 million residents over the next three to five years, although that scale would depend on the programme continuing to expand well beyond its initial target.
Beyond India, the company says sales in South East Asia and the Middle East grew 35%, while middleware software revenue doubled as laboratories moved further towards connected diagnostics. That software links instruments to laboratory information systems, a shift that reflects broader demand for digitised, networked testing equipment rather than standalone machines. Transasia has also highlighted its employee sentiment, saying its Glassdoor rating has risen from 2.8 to 4.0, which it sees as evidence that morale is improving alongside commercial performance.
The company’s long-term ambition is to join the top 20 global in vitro diagnostics groups, a field dominated by far larger multinational players. For Transasia, the immediate challenge is to turn its domestic turnaround and public-sector traction into a more durable export story. Its recent numbers suggest that plan is at least starting to gain momentum, even if the distance to global scale remains substantial.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
